Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.
Xilio Therapeutics, Inc. develops masked immuno-oncology therapies for people living with cancer. Company news centers on its proprietary masking technology, which is designed to localize anti-tumor activity within the tumor microenvironment, and on pipeline updates for masked biologics and multi-specific I-O molecules.
Recurring developments include preclinical data for programs such as XTX601, a masked T cell engager targeting CLDN18.2, updates on XTX501, a bispecific PD-1 / masked IL-2 program, and disclosures involving masked T cell engager programs targeting PSMA and STEAP1. News also covers financial results, scientific conference presentations, inducement equity grants, board composition, and capital-structure actions.
Xilio Therapeutics (Nasdaq: XLO) will present new preclinical data for its masked T cell engager program targeting CLDN18.2 at the AACR Annual Meeting, April 17-22, 2026 in San Diego.
The poster, titled Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell Engager, is scheduled for Monday, April 20, 2026, 9:00 a.m.–12:00 p.m. PST at Poster Section 10, Poster Board 11 (Abstract No. 1619).
Xilio Therapeutics (Nasdaq: XLO) will implement a 1-for-14 reverse stock split effective 5:00 p.m. ET on March 13, 2026, with split-adjusted trading beginning March 16, 2026 under ticker XLO and new CUSIP 98422T209. The split reduces outstanding shares from approximately 73.5 million to approximately 5.2 million.
The company said one primary goal is to increase its per-share market price to enable regaining compliance with Nasdaq Capital Market minimum bid price requirements. Warrants, equity awards and plan share pools will be proportionately adjusted; fractional shares will receive cash payments.
Xilio Therapeutics (Nasdaq: XLO) said company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 9, 2026 at 3:00 p.m. ET.
A live webcast will be available at the company investor site ir.xiliotx.com, with a replay archived for 30 days after the presentation.
Xilio Therapeutics (Nasdaq: XLO) granted non-qualified stock options to two new employees effective March 1, 2026 under its 2022 Inducement Stock Incentive Plan. The awards total 50,050 options with an exercise price of $0.5283 per share, equal to the February 27, 2026 closing price.
Each option has a ten-year term and vests 25% after one year, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service and plan terms.
Xilio Therapeutics (Nasdaq: XLO) priced an underwritten offering of 74,780,300 pre-funded warrants at $0.5349 each, exercisable for one share at $0.0001 per share. Gross proceeds are expected to be approximately $40.0 million, with closing on or about February 13, 2026, subject to customary conditions.
Investors include Coastlands Capital (lead), Gilead Sciences, OrbiMed, Perceptive Advisors and others. Leerink Partners is sole bookrunner. Net proceeds will be used to advance product development, working capital and general corporate purposes.
Xilio Therapeutics (NASDAQ: XLO) reported $35.8 million in gross proceeds from Series B warrant exercises and estimates $137.5 million in cash and cash equivalents as of December 31, 2025. The company said this funding extends its anticipated cash runway into the second quarter of 2027. Recent program updates include a development milestone for a masked antibody program under the AbbVie collaboration and nomination of a development candidate for a wholly owned masked T cell engager targeting CLDN18.2. Corporate changes include the appointment of Sara Bonstein as chair of the board. Anticipated next milestones include an IND submission for XTX501 in mid-2026 and initial Phase 1 data for XTX501 in H2 2027, subject to FDA clearance.
Xilio Therapeutics (Nasdaq: XLO) reported clinical and financial updates on Nov 13, 2025. At SITC, Phase 2 vilastobart data showed a 40% ORR in heavily pretreated, plasma TMB-high (≥10 mut/Mb) MSS mCRC patients without liver metastases, with p=0.05 correlation between plasma TMB and response. Phase 1 efarindodekin alfa monotherapy data showed promising anti-tumor activity and tolerability; XTX501 (bispecific PD-1/masked IL-2) is advancing toward a planned IND in mid-2026. Xilio presented preclinical masked T cell engager data and nominated a PSMA development candidate. Financials: $103.8M cash as of Sept 30, 2025; Q3 collaboration revenue $19.1M; net loss $16.3M. Company expects runway into Q1 2027.
Xilio Therapeutics (NASDAQ: XLO) reported late-breaking Phase 2 data for vilastobart plus atezolizumab at SITC on Nov 7, 2025 showing a 40% objective response rate (ORR) in heavily pre-treated patients with MSS metastatic colorectal cancer (mCRC) who had no liver metastases and high plasma TMB (≥10 mut/Mb).
Data cutoff was May 12, 2025: 44 patients treated (100 mg Q6W vilastobart + 1200 mg Q3W atezolizumab), 27 without liver metastases, 24 evaluable for plasma TMB. Company estimates ~55% of non‑MSI‑H CRC are plasma TMB‑high. Responses included tumor reductions up to 71%. Safety: mostly Grade 1–2, 5% discontinued for treatment‑related AEs and 7% experienced colitis. Xilio will host a conference call/webcast on Nov 10, 2025 at 4:30 p.m. ET.
Xilio Therapeutics (NASDAQ: XLO) presented preclinical and clinical data at SITC 2025 highlighting its masked immunotherapy platform and clinical-stage programs efarindodekin alfa (tumor-activated IL-12) and vilastobart (tumor-activated, Fc-enhanced anti-CTLA-4).
Key clinical facts: as of Sept 2, 2025 62 patients received efarindodekin alfa in Phase 1 dose escalation; doses exceeded recombinant IL-12 by >100-fold; two partial responses observed (confirmed PR: 33% reduction; unconfirmed PR: 55% reduction). Vilastobart Phase 2 ctDNA data (cutoff May 12, 2025) showed ≥75% ctDNA reductions correlated with radiographic response in 23 evaluable MSS mCRC patients without liver metastases.
Xilio Therapeutics (Nasdaq: XLO) granted a non-qualified stock option to purchase 5,700 shares to a new employee effective November 1, 2025, under its 2022 Inducement Stock Incentive Plan. The exercise price is $0.7967 per share, equal to the closing price on October 31, 2025. Each option has a 10-year term.
Vesting: 25% vests on the first anniversary of employment, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service and plan/option agreement terms. The grant was made under Nasdaq Listing Rule 5635(c)(4).